



## Supporting Information

General preparation of (+)-(1S,2S)- and (-)-(1R,2R)-*trans*-1-ethoxy-2-alkyl/aryl-cyclopropyl-acetates [(+)-5b-e, (-)-5b-e] – Kinetic resolution of the cyclopropylacetates ( $\pm$ )-5b-e


In a typical procedure, acetate, lipase, butanol and diisopropyl ether are combined and stirred at 40 °C. The reaction is monitored by GLC and stirring is continued until one enantiomer cannot be detected anymore.

Determination of the enantiomeric excess during the reaction: to 0.25 ml of the mixture 0.5 ml of hydrochloric acid (10 %) is added and extracted with 1 ml of *n*-hexane. The organic phase is dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and 1 μl is detected by GLC.

To stop the reaction, the mixture is poured on cold hydrochloric acid (10 %) and rapidly extracted with *n*-hexane. For better phase separation, the flask can be dipped into an ultrasonic bath. The combined organic phases are dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and purified by column chromatography. The products can be obtained as colourless oils.

(+)-(1S,2S)-2-Pentyl-1-ethoxy-cyclopropan-1-ol acetate (+)-5b

450 mg (2.10 mmol) ( $\pm$ )-5b, butanol: 4.5 ml, lipase CALB: 450 mg; diisopropyl ether: 45 ml; reaction time: 11 d; yield: 185 mg (0.86 mmol; 84 %).

(-)-(1R,2R)-2-Pentyl-1-ethoxy-cyclopropan-1-ol acetate (-)-5b


60 mg (0.28 mmol) (**±**)-**5b**, butanol: 0.6 ml, lipase PCL: 60 mg, diisopropyl ether: 6 ml; reaction time: 18 d; yield: 21 mg (0.1 mmol; 70 %).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ [ppm] = 0.63 (t, *J* = 6.35 Hz, 1H, CH), 0.78 – 1.72 (m, 16H, 5xCH<sub>2</sub>, 2xCH<sub>3</sub>), 2.05 (s, 3H, CH<sub>3</sub>), 3.60 – 3.88 (m, 2H, OCH<sub>2</sub>).


<sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ [ppm] = 14.47 (CH<sub>3</sub>), 15.77 (CH<sub>3</sub>), 17.19 (CH<sub>2</sub>), 21.67 (CH<sub>3</sub>), 22.98 (CH<sub>2</sub>), 26.12 (CH), 28.23, 28.90, 32.08 (3xCH<sub>2</sub>), 64.77 (OCH<sub>2</sub>), 89.92 (C<sub>q</sub>), 170.37 (C<sub>q</sub>).

IR (KBr-pressling):  $\tilde{\nu}$  [cm<sup>-1</sup>] = 3028 – 2857, 1750, 1217, 1176.

C<sub>12</sub>H<sub>22</sub>O<sub>3</sub> (214.30): calculated: C: 67.26 %, H 10.35 %, found: C: 67.22 %, H: 10.37 %.

(+)-(1S,2S)-2-Hexyl-1-ethoxy-cyclopropan-1-ol acetate (+)-5c

150 mg (0.66 mmol) (**±**)-**5c**, butanol: 1.5 ml, lipase CALB: 150 mg, diisopropyl ether: 15 ml; reaction time: 7 d; yield: 47 mg (0.21 mmol; 64 %).

(-)-(1R,2R)-2-Hexyl-1-ethoxy-cyclopropan-1-ol acetate (-)-5c

100 mg (0.44 mmol) (**±**)-**5c**, butanol: 1 ml, lipase PCL: 100 mg, diisopropyl ether: 10 ml; reaction time: 16 d; yield: 16 mg (0.07 mmol; 34 %).


<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ [ppm] = 0.63 (t, *J* = 6.23 Hz, 1H, CH), 0.86 – 1.69 (m, 18H, 6xCH<sub>2</sub>, 2xCH<sub>3</sub>), 2.05 (s, 3H, CH<sub>3</sub>), 3.60 – 3.88 (m, 2H, OCH<sub>2</sub>).

<sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ [ppm] = 14.48 (CH<sub>3</sub>), 15.77 (CH<sub>3</sub>), 17.20 (CH<sub>2</sub>), 21.67 (CH<sub>3</sub>), 23.03 (CH<sub>2</sub>), 26.12 (CH), 28.28, 29.18, 29.54, 32.18 (4xCH<sub>2</sub>), 64.78 (OCH<sub>2</sub>), 89.93 (C<sub>q</sub>), 170.35 (C<sub>q</sub>).

IR (KBr-pressling):  $\tilde{\nu}$  [cm<sup>-1</sup>] = 3022 – 2862, 1750, 1222, 1170.


$C_{13}H_{24}O_3$  (228.33): calculated: C 68.38 %, H 10.59 %, found: C 68.50 %, H 10.78 %.

(+)-(1S,2S)-2-Heptyl-1-ethoxy-cyclopropan-1-ol acetate (**±**)-5d



400 mg (1.65 mmol) (**±**)-5d, butanol: 4 ml, lipase CALB: 400 mg, diisopropyl ether: 40 ml; reaction time: 4 d; yield: 171 mg (0.71 mmol; 86 %).

(-)-(1R,2R)-2-Heptyl-1-ethoxy-cyclopropan-1-ol acetate (**-**)-5d




505 mg (2.08 mmol) (**±**)-5d, butanol: 5 ml, lipase PCL: 52 mg, diisopropyl ether: 50 ml; reaction time: 36 d; yield: 190 mg (0.78 mmol; 75 %).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ [ppm] = 0.63 (t, *J* = 6.33 Hz, 1H, CH), 0.86 – 0.92 (m, 3H, CH<sub>3</sub>), 0.99 – 1.79 (m, 17H, 7xCH<sub>2</sub>, CH<sub>3</sub>), 2.05 (s, 3H, CH<sub>3</sub>), 3.60 – 3.88 (m, 2H, OCH<sub>2</sub>).

<sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ [ppm] = 14.49 (CH<sub>3</sub>), 15.78 (CH<sub>3</sub>), 17.19 (CH<sub>2</sub>), 21.67 (CH<sub>3</sub>), 23.06 (CH<sub>2</sub>), 26.12 (CH), 28.27, 29.23, 29.63, 29.84, 32.26 (5xCH<sub>2</sub>), 64.77 (OCH<sub>2</sub>), 89.92 (C<sub>q</sub>), 170.34 (C<sub>q</sub>).


IR (KBr-pressling):  $\tilde{\nu}$  [cm<sup>-1</sup>] = 3017 – 2851, 1755, 1207, 1165.

(+)-(1S,2S)-2-Benzyl-1-ethoxy-cyclopropan-1-ol acetate (**±**)-5e



710 mg (3.03 mmol) (**±**)-5e, butanol: 7.1 ml, lipase CALB <sup>1</sup>: 710 mg, diisopropyl ether: 71 ml; reaction time: 3 d; yield: 350 mg (1.49 mmol; 98 %).

<sup>1</sup> Lipase from *Candida antartica* Novozym 435, immobilised

(-)-(1R,2R)-2-Benzyl-1-ethoxy-cyclopropan-1-ol acetate (-)-5e

300 mg (1.35 mmol) (**±-5e**), butanol: 3 ml, lipase PCL<sup>2</sup>: 300 mg, diisopropyl ether: 31 ml; reaction time: 7 d; yield: 82 mg (0.33 mmol; 52 %).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ [ppm] = 0.88 (t, *J* = 6.94 Hz, 1H, CH), 1.17 – 1.33 (m, 5H, CH<sub>2</sub>, CH<sub>3</sub>), 2.08 (s, 3H, CH<sub>3</sub>), 2.49 – 2.69 (dd, *J* = 8.69 Hz, *J* = 14.97 Hz, 1H, CH<sub>2</sub>), 3.06 – 3.21 (dd, *J* = 5.67 Hz, *J* = 14.93 Hz, 1H, CH<sub>2</sub>), 3.69 – 3.98 (m, 2H, OCH<sub>2</sub>), 7.22 – 7.34 (m, 5H, 5xCH<sub>arom</sub>).

<sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ [ppm] = 15.84 (CH<sub>3</sub>), 17.70 (CH<sub>2</sub>), 21.65 (CH<sub>3</sub>), 26.78 (CH), 34.19 (CH<sub>2</sub>), 65.05 (OCH<sub>2</sub>), 89.55 (C<sub>q</sub>), 126.46, 127.52, 128.76, 128.89 (5xCH<sub>arom</sub>), 141.24 (C<sub>q</sub>), 170.32 (C<sub>q</sub>).

IR (KBr-pressling):  $\tilde{\nu}$  [cm<sup>-1</sup>] = 3022 – 2851, 1750, 1217, 1160.

C<sub>14</sub>H<sub>18</sub>O<sub>3</sub> (234.30): calculated C: 71.77 %, H: 7.74 %, found: C: 71.80 %, H: 7.89 %.

<sup>2</sup> Lipase from *Pseudomonas cepacia* from Fluka, ~ 50 U/mg